The biotech companies' agreement covers manufacture of an anti-VISTA antibody developed for solid tumors that are unresponsive to existing treatments.
TTHX1114, an engineered form of FGF-1, is designed to stimulate proliferation and migration of corneal endothelial cells to restore lost vision in patients with corneal diseases.
Expert says a company seeking flexible ways of making high-value, low-volume products should try cell-free expression as the method requires minimal manufacturing infrastructure and process development requirements.
BrightGene Bio-Medical Technology Co., said it has successfully manufactured the active pharmaceutical ingredients (APIs) of remdesivir (GS-5734), the Gilead Science antiviral candidate being tested in China human clinical trials as a treatment for 2019-nCoV novel coronavirus.
CCRM and GE Healthcare Life Sciences are working to develop proprietary media formulations for Platelet BioGenesis to enable the efficient differentiation of stem cells.
The biopharm industry has been automating aspects of production, handling, and transfer processes for decades. Now, process monitoring, in particular, has become a more recent focus partly due to growing regulatory support for quality by design and process analytical technology. But while it may improve product quality and manufacturing efficiency, automated in-process monitoring generates huge amounts of data.
Please wait while you are redirected to the right page...